Abstract: Devices and methods for mixing and preparing therapeutic pellets are described. In one aspect, the present disclosure may include a medical device for mixing and preparing pharmaceuticals. The medical device may include a body sized and shaped to be supported by a human hand. The body may be elastically flexible between a relaxed shape and a flexed shape. In the relaxed shape, the body may form a basin and may be shaped and sized to receive a vessel for mixing or forming the therapeutic pellets. In the flexed shape, the bowl may be configured for controlled pouring of the therapeutic pellets.

Abstract: An example system includes a collar; a first stimulating electrode array positioned on the collar and configured to delivery stimulation therapy to a patient; a second stimulating electrode array being positioned on the collar and configured to deliver stimulation therapy to the patient; a sensor array being positioned on the collar and configured to detect one or more features indicative of laryngeal muscle activity of the patient; and a controller configured to control stimulation therapy to be delivered via the first stimulating electrode array and the second stimulating electrode array.

Abstract: Compositions and methods of making hybrid polypeptides and other polymers are disclosed. For example, functionalized tRNA having a functional molecule including a benzoic acid or benzoic acid derivative acylated to the 3? nucleotide of a tRNA are provided. Functionalized tRNA having a functional molecule including a malonic acid or malonic acid derivative acylated to the 3? nucleotide of a tRNA are also provided. Methods of using the functionalized tRNA for making compounds including the functional molecule are also provided. The methods typically include providing or expressing a messenger RNA (mRNA) encoding the target polypeptide in a translation system including one or more functionalized tRNA wherein each functionalized tRNA recognizes at least one codon such that its functional molecule is incorporated into the polypeptide or other polymer during translation. The incorporation of the functional molecule can occur in vitro in a cell-free translation system, or in vivo in a host cell.

Abstract: Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive S. aureus (VSE), vancomycin-resistant enterococci (VRE), or combinations thereof. The compounds can be administered as the neutral free acid or free base or can be administered as a pharmaceutically acceptable acid-addition or base-addition salt. The compounds can be formulated with one or more pharmaceutically acceptable excipients to prepare pharmaceutical compositions. The compounds can be administered by a variety of routes of administration including enteral, parenteral, topical, or transmucosal.

Abstract: Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive S. aureus (VSE), vancomycin-resistant enterococci (VRE), or combinations thereof. The compounds can be administered as the neutral free acid or free base or can be administered as a pharmaceutically acceptable acid-addition or base-addition salt. The compounds can be formulated with one or more pharmaceutically acceptable excipients to prepare pharmaceutical compositions. The compounds can be administered by a variety of routes of administration including enteral, parenteral, topical, or transmucosal.

Abstract: For frames sequentially functioning as a reference frame in a video sequence frame set, a motion estimate set is accessed. One motion estimate characterizes motion associated with pixels of each region of the reference frame in relation to regions of one frame of the set of frames, which is temporally displaced in time with respect to other frames in the set of frames. An additional motion estimate characterizes motion associated with pixels of each reference frame region in relation to a second frame of the set, which is temporally displaced from the one frame and other frames of the frame set. A temporal image prediction set, corresponding to the first and additional motion estimate, is predicted, based on an alignment of the reference frame regions over the frame set. The temporal image predictions are blended and a temporal predictor is generated over the frame set based on the blending.

Abstract: The present invention provides peptide-based phosphorylation catalysts (PBPC's) for the asymmetric monophosphorylation of cyclitols, particularly myo-inositols. The PBPC's of the invention effect a regio and enantioselective phosphorylation of a myo-inositol in a manner analogous to enzymatic kinases, thereby functioning as effective “kinase mimics.” Although orders of magnitude less complex in terms of structure than macromolecular proteins, the PBPC's of the invention control product formation with high enantioselectivity (>98% ee). The synthetic (+)-myo-inositol-1-phosphate is optically and spectroscopically equivalent to naturally occuring compound. The ability of the low molecular weight PBPC's of the present invention to mimic stereoselective enzymes represents a powerful approach toward catalytic asymmetric synthesis of biologically important molecules, and for mechanistic modeling of biochemical transformations to enable their use in drug applications.

Abstract: The present invention provides peptide-based phosphorylation catalysts (PBPC's) for the asymmetric monophosphorylation of cyclitols, particularly myo-inositols. The PBPC's of the invention effect a regio and enantioselective phosphorylation of a myo-inositol in a manner analogous to enzymatic kinases, thereby functioning as effective “kinase mimics.” Although orders of magnitude less complex in terms of structure than macromolecular proteins, the PBPC's of the invention control product formation with high enantioselectivity (>98% ee). The synthetic (+)-myo-inositol-1-phosphate is optically and spectroscopically equivalent to naturally occuring compound. The ability of the low molecular weight PBPC's of the present invention to mimic stereoselective enzymes represents a powerful approach toward catalytic asymmetric synthesis of biologically important molecules, and for mechanistic modeling of biochemical transformations to enable their use in drug applications.

Abstract: A method for synthesizing conformationally restricted amino acids, peptides, and peptidomimetics by ring closing metathesis. The method includes the steps of synthesizing a peptide precursor containing first and second unsaturated C--C bonds and contacting the peptide precursor with a RCM catalyst to yield a conformationally restricted peptide. Suitable peptide precursors may contain two or more unsaturated C--C bonds. These bonds may be olefinic bonds and may be contained in first and second alkenyl groups which may be allyl groups. The RCM catalyst may be a Ruthenium or Osmium carbene complex catalyst and more specifically, a Ruthenium or Osmium carbene complex catalyst that includes a Ruthenium or Osmium metal center that is in a +2 oxidation state, has an electron count of 16, and is pentacoordinated. The method may be carried out using solid-phase-peptide-synthesis techniques.

Abstract: A protective helmet assembly including an outer impact shell and an inner impact attenuation liner assembly wherein the inner liner assembly includes an adjustable headband assembly comprised of a front headband member and a rear spring-loaded headband member under the control of a chinstrap into a fitted configuration about the head of the user by a clip assembly. The inner impact attenuation liner assembly is mounted within the outer impact shell to separate therefrom under predetermined load conditions.